China Innovation, Large Market Continue To Lure Foreign Investment

Robust Activity Despite De-Risking

High patient needs, a large healthcare market and innovation potential in the biotech sector in China still appear to be maintaining and attracting investments by overseas biopharma companies, including by Bayer and Lilly in biotech start-ups and Lilly in manufacturing.

Investment and potential growth
Global biopharmas expand their investments in manufacturing upgrade and biotech innovation in China (Shutterstock)
Xu Hu

Read more by Xu Hu

Xu is a senior reporter and covers aspects on policy and regulations in China pharma industry within the APAC Pharma news team.

More from Scrip

More from Business